Feature | July 03, 2012

Cardiovascular Risk May Vary According to the Distribution of Epicardial, Not Abdominal, Fat

July 3, 2012 — Researchers have announced the results of a study that highlights the use of echocardiography in identifying the epicardial fat pad that is strongly associated with arterial stiffness.

A poster based on the study, which was conducted by a team led by primary investigator Dr. Hitomi Sakamoto and lead author Dr. Norihisa Toh of Okayama University Hospital, Okayama, Japan, will be displayed on Sunday, July 1 from 9:30 a.m. to 4:30 p.m. in the exhibit and poster hall during the American Society of Echocardiography (ASE) 23rd Annual Scientific Sessions. Investigators will be available in the hall from 12:15 p.m. to 1:45 p.m. The conference will be held from June 27 to July 3, 2012, at the Gaylord National in National Harbor, MD.

In a unique study, investigators were able to determine that fatty deposits around the heart — known as epicardial fat — identified by echocardiography is strongly associated with increased stiffness of the arteries in the body. This is an important finding due to the fact that the fat around the heart, as opposed to increased abdominal fat, predicts increased stiffness of the arteries. Arterial stiffness is known to be a marker of an increased risk of heart disease.


Related Content

News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
Subscribe Now